Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements review uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabil... https://stephens198rsl5.blogitright.com/profile